MYGN — Myriad Genetics Income Statement
0.000.00%
Last trade - 00:00
- $2.51bn
- $2.45bn
- $753.20m
- 71
- 32
- 100
- 75
2019 June 30th | 2020 June 30th | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 851 | 639 | 691 | 678 | 753 |
Cost of Revenue | |||||
Gross Profit | 650 | 453 | 493 | 476 | 517 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 844 | 869 | 741 | 819 | 1,011 |
Operating Profit | 7.6 | -231 | -50 | -141 | -257 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0 | -223 | -57.1 | -141 | -262 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4.4 | -200 | -24.5 | -112 | -263 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 4.6 | -200 | -27.2 | -112 | -263 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 4.6 | -200 | -27.2 | -112 | -263 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.267 | -1.82 | -0.948 | -1.25 | -2.23 |